Table 1.
Baseline characteristics
| Total n = 362 |
Hepatotoxicity n = 8 |
No hepatotoxicity n = 354 |
p* | |
|---|---|---|---|---|
| Age, median (IQR) | 38.5 (33.7–45.8) | 39.6 (32.7–40.7) | 38.5 (33.8–45.9) | 0.479 |
| Female, n (%) | 133 (36.7) | 6 (75.0) | 127 (35.9) | 0.055 |
| Naïve patients, n (%) | 58 (16.0) | 1 (12.5) | 57 (16.1) | 0.783 |
| Risk group, n (%) | ||||
| Eterosexual | 181 (50.0) | 4 (50.0) | 177 (50.0) | 0.213 |
| MSM | 83 (22.9) | 0 (0.0) | 83 (23.5) | |
| IVDUs | 84 (23.2) | 4 (50.0) | 80 (22.6) | |
| Others | 14 (3.9) | 0 (0.0) | 14 (3.9) | |
| Caucasian, n (%) | 330 (91.1) | 7 (87.5) | 323 (91.2) | 0.527 |
| BMI, median (IQR) | 22.4 (20.5–24.5) | 19.9 (18.3–22.0) | 22.6 (20.6–24.5) | 0.017 |
| AIDS, n (%) | 63 (17.4) | 1 (12.5) | 62 (17.5) | 0.999 |
| CD4+/mL, median (IQR) | 436 (306–593) | 555 (479–611) | 433 (300–592) | 0.157 |
| HIV-RNA log10 cp/mL,median (IQR) | 1.75 (0.00–4.09) | 0.00 (0.00–2.16) | 1.79 (0.00–4.10) | 0.229 |
| HCV coinfection, n (%) | 131 (31.2) | 6 (75.5) | 107 (30.2) | 0.013 |
| HBV coinfection, n (%) | 21 (5.8) | 1 (12.5) | 20 (5.65) | 0.383 |
| AST U/L, median (IQR) | 26 (20–38) | 58 (29–92) | 26 (20–37) | 0.041 |
| ALT U/L, median (IQR) | 28 (18–50) | 82 (37–122) | 27 (18–49) | 0.047 |
| ARV backbone, n (%) | ||||
| ABC | 32 (8.8) | 1 (12.5) | 31 (8.8) | 0.311 |
| AZT/DDI/D4T | 223 (61.6) | 7 (87.5) | 216 (61.0) | |
| TDF | 86 (23.7) | 0 (0.0) | 86 (24.3) | |
| Others | 21 (5.8) | 0 (0.0) | 21 (5.9) | |
Abbreviations: n number, yrs. years, IQR Inter Quartile Range, MSM Man how have sex with man, IVDUs Intra venous drug users, BMI Body Mass Index, cps copies, ABC abacavir, TDF tenofovir diproxil fumarate. *p-values are for χ2 or Fisher’s exact test and Mann-Whitney test